January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2014; 130(23): e272–274]. Circulation. 2014;130(23):e199-e267.
Frost JL, Campos-Outcalt D, Hoelting D, et al. Atrial fibrillation guideline summary. Ann Fam Med. 2017;15(5):490-491.
Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4-20.
Gahungu N, Trueick R, Coopes M, et al. Paroxysmal atrial fibrillation. BMJ. 2021;375:e058568.
Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) [published corrections appear in Eur Heart J 2021; 42(5): 507, Eur Heart J. 2021; 42(5): 546–547, and Eur Heart J. 2021; 42(40): 4194]. Eur Heart J. 2021;42(5):373-498.
Davidson KW, Barry MJ, Mangione CM, et al. Screening for atrial fibrillation: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(4):360-367.
Moran PS, Teljeur C, Ryan M, et al. Systematic screening for the detection of atrial fibrillation. Cochrane Database Syst Rev. 2016(6):CD009586.
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published corrections appear in Circulation. 2024; 149(1): e167 and Circulation. 2024; 149(9): e936]. Circulation. 2024;149(1):e1-e156.
Taggar JS, Coleman T, Lewis S, et al. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(12):1330-1338.
Zungsontiporn N, Link MS. Newer technologies for detection of atrial fibrillation. BMJ. 2018;363:k3946.
Gutierrez C, Blanchard DG. Diagnosis and treatment of atrial fibrillation. Am Fam Physician. 2016;94(6):442-452.
Prasitlumkum N, Cheungpasitporn W, Chokesuwattanaskul A, et al. Diagnostic accuracy of smart gadgets/wearable devices in detecting atrial fibrillation: a systematic review and meta-analysis. Arch Cardiovasc Dis. 2021;114(1):4-16.
Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-Stroke and CHA2DS2-VASc scores. J Am Heart Assoc. 2017;6(7):e006490.
Andrade JG, Wells GA, Deyell MW, et al.; EARLY-AF Investigators. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384(4):305-315.
Perry M, Kemmis Betty S, Downes N, et al.; Guideline Committee. Atrial fibrillation: diagnosis and management-summary of NICE guidance. BMJ. 2021;373:n1150.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2019; 74(4): 599]. J Am Coll Cardiol. 2019;74(1):104-132.
Aggarwal R, Ruff CT, Virdone S, et al. Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants. Circulation. 2023;148(12):936-946.
Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121-1201.
Carnicelli AP, Hong H, Connolly SJ, et al.; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient level network meta-analyses of randomized clinical trials with interaction testing by age and sex [published correction appears in Circulation 2022; 145(8): e640]. Circulation. 2022;145(4):242-255.
López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis [published corrections appear in BMJ. 2017; 359: j5631 and BMJ. 2018; 361: k2295]. BMJ. 2017;359:j5058.
Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2018(3):CD008980.
Olshansky B, Rosenfeld LE, Warner AL, et al.; AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-1208.
Van Gelder IC, Hagens VE, Bosker HA, et al.; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-1840.
Van Gelder IC, Groenveld HF, Crijns HJGM, et al.; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-1373.
Kotecha D, Bunting KV, Gill SK, et al.; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA. 2020;324(24):2497-2508.
Chung MK, Eckhardt LL, Chen LY, et al.; American Heart Association Electrocardiography and Arrhythmias Committee and Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Lifestyle and Cardiometabolic Health. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020;141(16):e750-e772.
Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050-2060.
Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020;382(1):20-28.
Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, et al.; RACE 7 ACWAS Investigators. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 2019;380(16):1499-1508.
Kirchhof P, Camm AJ, Goette A, et al.; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305-1316.
Chen S, Yin Y, Krucoff MW. Should rhythm control be preferred in younger atrial fibrillation patients?. J Interv Card Electrophysiol. 2012;35(1):71-80.
Bhatia S, Sugrue A, Asirvatham S. Atrial fibrillation: beyond rate control. Mayo Clin Proc. 2018;93(3):373-380.
Tseng AS, Kowlgi GN, DeSimone CV. Antiarrhythmic drugs for atrial fibrillation in the outpatient setting: common clinical scenarios and pearls for the primary care clinician. Mayo Clin Proc. 2021;96(8):2230-2242.
Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-389.
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Arrhythm. 2017;33(5):369-409.
Marrouche NF, Brachmann J, Andresen D, et al.; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-427.
Chen HS, Wen JM, Wu SN, et al. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst Rev. 2012(4):CD007101.
Nyong J, Amit G, Adler AJ, et al. Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. Cochrane Database Syst Rev. 2016(11):CD012088.
Gutierrez C, Blanchard DG. Atrial fibrillation: diagnosis and treatment. Am Fam Physician. 2011;83(1):61-68.
King DE, Dickerson LM, Sack JL. Acute management of atrial fibrillation: part I. Rate and rhythm control. Am Fam Physician. 2002;66(2):249-256.
King DE, Dickerson LM, Sack JL. Acute management of atrial fibrillation: part II. Prevention of thromboembolic complications. Am Fam Physician. 2002;66(2):261-264.
Dell’Orfano JT, Luck JC, Wolbrette DL, et al. Drugs for conversion of atrial fibrillation. Am Fam Physician. 1998;58(2):471-480.
Akhtar W, Reeves WC, Movahed A. Indications for anticoagulation in atrial fibrillation [published correction appears in Am Fam Physician. 1999; 59(5): 1122]. Am Fam Physician. 1998;58(1):130-136.